Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash & Equivalents (2024 - 2025)

Prelude Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $35.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 182.64% year-over-year to $35.3 million; the TTM value through Dec 2025 reached $35.3 million, up 182.64%, while the annual FY2025 figure was $35.3 million, 182.64% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $35.3 million at Prelude Therapeutics, down from $50.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $103.1 million in Q1 2025 and bottomed at $12.5 million in Q4 2024.